PROM1 and cancer: Our results indicate the presence of a high percentage (≥70%) of CD133+ cells in the three cancer cell lines analyzed (B16F10 murine melanoma, MCF7 breast cancer and INER51 lung cancer cells) as assessed by immunocytochemistry.